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A B S T R A C T
Objectives: We examined health care use in conjunction with primary prophylaxis use of
colony stimulating factors (CSF) during patients’ initial course of chemotherapy.
Methods: This retrospective cohort study identified adults aged 25 years and older with a
diagnosis of breast, colorectal, or nonsmall cell lung cancer between 2002 and 2005 from the
Western Washington Surveillance Epidemiology and End Results Puget Sound registry. We
linked these records to health insurance claims from four payers representing 75% of those
insured in the state. Claims records were used to determine chemotherapy regimen type, CSF
use, febrile neutropenia occurrences, and supportive care. Chemotherapy regimens were cat-
egorized as conferring high, intermediate, or low risk of myelosuppression according to the
National Comprehensive Cancer Network guidelines. CSF use was described as primary pro-
phylaxis, other, or none. Antibiotics and antifungal and antiviral agents per National Compre-
hensive Cancer Network guidelines for supportive care for cancer infection were categorized
using Healthcare Common Procedure Coding System and National Drug Code assignments.
Results: Use of CSF as primary prophylaxis is not significantly associated with a reduction
in antibiotic use or inpatient or outpatient visits. Primary prophylactic CSF use was associ-
ated with less use of antiviral drugs.
Conclusions: CSF use is not associated with a reduction in health care use, with the excep-
tion of antiviral drug use. Given the expense associated with CSF use, pragmatic trials and
additional research are needed to further assess the affects of CSF on health care use.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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al SoIntroduction
Cancer patients who receive cytotoxic chemotherapy are at
risk of developing febrile neutropenia (FN), a lack of white
blood cells that puts patients at high risk of hospitalization
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Published by Elsevier Inc.doi:10.1016/j.jval.2010.09.005[1–3] and death due to infection [4]. In clinical trials, prophy-
lactic treatment with granulocyte colony stimulating fac-
tors (CSF) at the start of chemotherapy can reduce the inci-
dence of FN by as much as 50% for chemotherapy regimens
with a high or intermediate risk of FN [5–11]. The American
Society for Clinical Oncology, the National Comprehensive
Research Center, 1100 Fairview Avenue N., M3-B232, Seattle, WA
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Research and Treatment of Cancer have published guide-
lines recommending the use of CSF agents as primary pro-
phylaxis when the patient’s chemotherapy regimen pos-
sesses a substantial risk of FN or other neutropenic event(s)
[12–14].
CSFs have been shown in clinical trials and two retrospec-
tive studies to reduce the risk for FN-related hospitalization
[11,15–17]. There are little data, however, concerning the in-
fluence of CSF on hospitalizations and other FN-related health
care use in usual practice settings. To address these questions,
we evaluated the association of CSF use, presence of FN, and
health care use for patients with breast, colorectal, or nons-
mall cell lung cancer who received myelosuppressive chemo-
therapy after linking Surveillance, Epidemiology, and End Re-
sults (SEER) cancer registry information to medical and
pharmacy claims data from four large health insurers in west-
ern Washington State.
Methods
Data sources
For this study, patient-level data obtained from the SEER Puget
Sound cancer registry were merged with health care claims
data from four regional payers: Medicare Region X, Washing-
ton State Medicaid, Premera Blue Cross, and Regence Blue
Shield of Washington. SEER records provided information
regarding cancer tumor characteristics, stage at diagnosis,
and survival. Health insurance status, cancer treatment in-
formation, and medical care use data were extracted from
the enrollment files and health care claims databases from
the four payers. The SEER Puget Sound registry provides
data on the incidence, treatment, and follow-up of all newly
diagnosed cancers, with the exception of nonmelanoma
skin cancers, occurring in residents of 13 counties in north-
west Washington State [18]. Certified abstractors obtain
data through visits to and reports from hospitals, outpatient
surgical centers, pathology laboratories, clinician offices,
and death certificates.
Premera Blue Cross and Regence Blue Shield, both non-
profit regional health plans, are two of the largest private
health insurers in Washington State. Premera Blue Cross
serves more than 1.4 million members in Washington State
[19] whereas Regence Blue Shield provides coverage for more
than one million Washington State residents [20]. Premera
and Regence data was pooled as commercial data for the pur-
pose of analysis.
Medicaid is managed under the auspices of the Washing-
ton State Department of Social and Health Services and the
Health Recovery Services Administration and serves approxi-
mately 330,000 clients in the Medicaid fee-for-service pro-
gram, which covers the full spectrum of care [21].
The Medicare program is administered by the Centers for
Medicare and Medicaid Services. Medicare is composed of part
A (inpatient hospital care) and part B (outpatient care, doctors’
services) [22]. Medicare outpatient prescription drug recordsfor Medicare patients are not available for the years of this
analysis because part D did not start until January 2006.
Study population
Approval was obtained from the appropriate institutional review
boards, and Health Insurance Portability and Accountability Act
authorization waivers were approved before database linkage
was conducted. To identify subjects with incident cases of the
relevant cancers, we cross-linked person-level identifiers (full
name, sex, date of birth, and zip code if available) from each
payer’s enrollment files with the SEER Puget Sound registry.
Linkage was limited to newly diagnosed cancers for each en-
rollee living within the SEER Puget Sound Registry’s 13-county
coverage area. Detailed inclusion and exclusion criteria for our
study population have been previously described [23].
Identification of CSF exposure, antibiotic use, and FN events
The focus of this study was to investigate the relationship
between guideline-determined prophylactic CSF use, subse-
quent development of FN, and specific measures of health
care and prescription drug use. Following NCCN guidelines,
CSF should be administered 24 to 72 hours after initial chemo-
therapy administration if used as primary prophylaxis [12].
First, patients were grouped into categories based on the
myelosuppressive risk posed by the chemotherapy regimen
they received. We used our previously described algorithm
[23] to identify the chemotherapy regimens commonly used
for breast, colorectal, and nonsmall cell lung cancers. The al-
gorithm considers the agents delivered and their timing in
relation to each other. The myelosuppressive risk of each reg-
imen (i.e., the risk for developing FN in the absence of CSF
administration) was based on the high, intermediate, and low-
risk chemotherapy regimen categories published by the NCCN
[12]. If a chemotherapy regimen was not categorized by NCCN,
a board-certified oncology pharmacist (JSM) categorized re-
maining regimens based on descriptions of their FN incidence
from the literature.
Then, using medical and pharmacy claims, we identified
the dates and type of initial chemotherapy agents used, the
initial date of CSF use, and FN events in relation to the initial
chemotherapy regimen. We defined CSF primary prophylaxis
as any use of CSF products within 3 days of the initiation of
chemotherapy.
Claims records also were used to determine the use of anti-
biotics and other supportive care associated with FN. Records
were searched for Healthcare Common Procedure Coding Sys-
tem and National Drug Code assignments for agents appearing
in the NCCN guidelines for supportive care for cancer infection
(online Appendices A and B, available at doi:10.1016/j.jval.
2010.09.005.) [24] from the initial date of the first chemother-
apy agent delivered to 14 days past the last date when a che-
motherapy agent code from the initial regimen appeared in
the patient’s claims records.
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We dichotomized CSF use as either use as primary prophy-
laxis or not. Of all CSF use, 34.4% was for filgrastim whereas
65.6% was for pegfilgrastim.
FN rates were stratified by cancer and by the myelosup-
pressive risk of the chemotherapy regimen. Payers were
grouped as Medicare, Medicaid, or commercial insurance
plans. Persons enrolled in more than one health plan during
the study period were assigned to the plan that contained the
majority of claims over the period of observation. We included
all medical and pharmacy claims from both plans for persons
who were enrolled in two plans.
Multivariate regression models were estimated to assess
the association between CSF use as primary prophylaxis and
components of health care use. Separate models were esti-
mated for each of five health care use outcomes. The depen-
dent variable for these models included counts over the period
of follow-up of claims for antibiotics, antifungal agents, anti-
viral agents, hospital admissions, and outpatient visits (i.e.,
the five health care use outcomes). All models were adjusted
for stage of cancer, age, sex, race, health plan type, comorbidi-
ties, myelosuppressive risk of the initial regimen, radiation
treatment within 30 days of diagnosis (yes or no), and surgery
within 30 days of diagnosis (yes or no). We conducted strati-
fied analysis by myelosuppressive risk level, and also inter-
acted myelosuppressive risk with CSF use to investigate the
hypothesis that any observed affect of CSF use on the depen-
dent variables was conditional upon the level of myelosup-
pressive risk. To account for possible colinearity between age
and health plan, we included age as a continuous variable
with both linear and quadratic terms in each model.
The distributions of the health care use outcomes were
skewed. They also contained a proportion of persons with no
use. We estimated the association between outcomes and pre-
dictors using multivariate regression models (ordinary least
squares); however, because of the skewed nature of the depen-
dent variables, we used the nonparametric bootstrap (1000 rep-
licates) to estimate coefficients and obtain valid standard errors.
We then checked the bootstrap distribution of the estimated co-
efficient of FN with a normal quantile plot for each outcome.
Table 1 – Demographic characteristics of patients at the tim
(NSCLC), or colorectal cancer (CRC) (N = 2728).
Characteristic Medicare Medicaid
Breast NSCLC CRC Breast NSCLC
Cancer stage:
number (%)
Local* 101 (33.9) 68 (9.0) 43 (10.3) 30 (34.9) 5 (4.5)
Regional 179 (60.1) 234 (31.2) 258 (61.9) 41 (47.7) 27 (24.1
Distant 18 (6) 449 (59.8) 116 (27.8) 15 (17.4) 80 (71.4
Age (mean, SD) 69.6 (7.2) 72.1 (6.0) 72.6 (6.7) 49.4 (8.2) 56.4 (8.3)
Sex (% women) 100 34.2 36.9 100 46.4
Race (% nonwhite) 5.0 5.5 6.0 23.3 20.5
Comorbidity score
(mean, SD)
1.5 (1.8) 2.5 (2.8) 2.4 (2.1) 0.7 (0.9) 1.6 (1.6)
SD, standard deviation.
* Does not include in situ and unknown staged cases.Only the coefficients for CSF in the models for antiviral agents ashowed deviation from normality. The bootstrap standard errors
of the coefficients were considerably larger from those obtained
from the multiple regression analyses for all use outcome
counts. We report all results in terms of the bootstrap estimates
with 95% bias-corrected, accelerated confidence intervals.
Results
Among 8354 patients identified with breast, colorectal, or nons-
mall cell lung cancer in the SEER and four health insurer data-
bases, a total of 2728 patients were identified as having received
chemotherapy during the 4-year time period. Table 1 lists the
haracteristics of these individuals by cancer and payer type.
cross all plans, the great majority of patients were white, and a
odest majority of nonbreast cancer patients were men. Pa-
ients with breast cancer had the fewest number of noncancer
omorbidities; patients with nonsmall cell lung cancer had the
reatest. Table 2 shows patients by cancer type and FN risk.
cross all plans, nearly three-quarters of breast cancer patients
eceived chemotherapy regimens considered high risk for FN. In
ontrast, only 5% of colorectal cancer patients received chemo-
herapy regimens with high FN risk. The overall rate of FN in the
opulation was 19.0%. For those receiving CSF, the rate was
0.2% and for those with no exposure to CSF the rate was 18.0%.
Table 3 presents the results of the five multivariate models.
e focus attention on the two variables related to FN and pri-
ary prophylaxis. A total of 349 FN events were observed across
ll cancer types. The presence of FN in these three cancer types
as associated with a statistically significant increase in antibi-
tic use (0.73 prescriptions). In addition, FN was significantly as-
ociated with an increase in inpatient admissions (3.27 admis-
ions) and outpatient visits (6.99 visits). These findings are
onsistent with the expectation that the presence of FN requires
reatment with antibiotics and additional visits to health care
acilities and providers.
Our primary hypothesis was that guideline-recommended
se of CSF agents would be associated with reduced health care
se. Table 3 shows the relationship between primary prophy-
axis with CSF and the five health care use outcomes. The results
uggest that CSF use as primary prophylaxis is not significantly
diagnosis with breast cancer, nonsmall cell lung cancer
Commercial (WA) Total across all plans
RC Breast NSCLC CRC Breast NSCLC CRC
(7.3) 250 (40.7) 13 (7.3) 29 (14.3) 381 (38.2) 86 (8.2) 77 (11.2)
(51.5) 334 (54.4) 48 (26.8) 111 (54.7) 554 (55.5) 309 (29.7) 404 (58.7)
(41.2) 30 (4.9) 118 (65.9) 63 (31.0) 63 (6.3) 647 (62.1) 207 (30.1)
(11.3) 50.6 (9.0) 58.4 (8.9) 53.0 (8.8) 56.2 (12.2) 68.1 (9.5) 65.1 (12.3)
2.7 100 44.1 50.3 100 37.2 41.4
3.5 8.5 7.8 11.3 8.7 7.5 9.3
(1.6) 0.5 (0.9) 1.1 (1.1) 0.8 (1.3) 0.8 (1.3) 2.2 (1.7) 1.8 (2.0)e of
C
5
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250 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 7 – 2 5 2outpatient visits, although the sign and magnitude of the coeffi-
cients suggested a trend toward lower use of antibiotics and vis-
its. One outcome, antiviral drug use, was significant and posi-
tively associated with CSF use.
Adding a term to the five models to reflect the interaction
between CSF use and myelosuppressive risk did not change the
main findings with the exception of the antiviral agents use
model. Subgroup analysis by myelosuppressive risk level was
also included. The findings from this analysis (online Appendix
C available at doi:10.1016/j.jval.2010.09.005) were the same as
he analysis using the CSF-myelosuppressive risk interac-
ion term. In this model we now find that compared to no
Table 2 – Description of initial chemotherapy regimens by
or colorectal cancer [CRC] and risk of febrile neutropenia (F
Mean (SD) FN risk *, as
determined by initial
chemo regimen
(number, [%])
Medicare Medic
Breast NSCLC CRC Breast NSC
High 188 (63.1) 79 (10.5) 16 (3.8) 71 (82.6) 25 (22
Intermediate 14 (4.7) 222 (29.6) 67 (16.1) 0 28 (25
Low 96 (32.2) 450 (59.9) 334 (80.1) 15 (17.4) 59 (52
SD, standard deviation.
* FN risk was determined by chemotherapy regimen for regimens w
is not documented, we determined FN risk based on the agent give
Table 3 – Estimated coefficients (mean bootstrap) and 95%
health care use.
Variable† Antibiotic agents Antiviral agents
Prophylactic colony
stimulating
factors
0.027 (0.242–0.147) 0.680 (0.116–1.450)
Febrile neutropenia 0.746 (0.304–2.11) 0.156 (0.338–0.743)
Regional stage 0.078 (0.327–0.125) 0.779 (0.450–1.122)
Distant stage 0.317 (0.711–0.085) 1.348 (0.873–1.786)
Colorectal cancer 0.171 (0.009–0.477) 0.192 (0.327–0.722)
Nonsmall cell lung
cancer
0.307 (0.012–0.608) 0.749 (0.256–1.390)
Age‡ 0.012 (0.027–0.063) 0.011 (0.149–0.083)
Age2‡ 0.000216 (0.000752–0.00011) 0.0001 (0.0009–0.00095)
Woman 0.041 (0.143–0.222) 0.356 (0.092–0.732)
Medicaid 0.846 (0.502–1.342) 0.055 (0.626–0.614)
Commercial 0.039 (0.335–0.141) 0.275 (0.759–0.270)
African American 0.098 (0.318–1.140) 0.632 (0.191–2.240)
Other nonwhite
race
0.254 (0.449–0.098) 0.449 (0.117–1.108)
Charlson score1 0.029 (0.163–0.181) 0.354 (0.017–0.743)
Charlson score2 0.240 (0.013,0.805) 0.256 (0.165–0.721)
Charlson score3 0.205 (0.075–0.522) 0.410 (0.066–1.031)
Charlson score4 0.030 (0.303–0.156) 0.518 (0.040–0.998)
Intermediate
myelosuppression
0.275 (0.045–0.866) 0.256 (0.669–0.187)
High
myelosuppression
0.174 (0.022–0.350) 0.021 (0.469–0.384)
Surgery within 30 d
of diagnosis
0.034 (0.187–0.132) 0.282 (0.160–0.881)
Radiation within
30 d of diagnosis
0.216 (0.516–0.000) 0.289 (0.740–0.177)
Follow-up time 0.000007 (0.00015–0.0004) 0.001 (0.0006–0.002)
R2 0.034 0.033
* Confidence intervals are bias-corrected and accelerated based on 1
† Reference group: stagelocal, cancer site breast, sexman, insur
surgery within 30 daysno, radiation within 30 daysno.
‡ Age is a linear model term; Age2 refers to the quadratic model term.CSF use, use of antiviral agents was significantly higher in
the low myelosuppressive risk group. The clinical signifi-
cance of this finding is unclear.
Conclusions
Febrile neutropenia is a serious and costly complication of
administering myelosuppressive chemotherapy to persons
with cancer. In clinical trials, prophylactic CSF has been
shown to reduce the incidence of FN. Models based on the
outcomes from these studies suggest that CSF may be cost-
er type (breast cancer, nonsmall cell lung cancer [NSCLC],
Commercial (WA) Total across all plans
CRC Breast NSCLC CRC Breast NSCLC CRC
5 (7.3) 475 (77.4) 29 (16.2) 16 (7.9) 734 (73.6) 133 (12.8) 37 (5.4)
5 (22.1) 39 (6.3) 49 (27.4) 41 (20.2) 53 (5.3) 299 (28.7) 123 (17.9)
8 (70.6) 100 (16.3) 101 (56.4) 146 (71.9) 211 (21.1) 610 (58.5) 528 (76.7)
cumented risk of FN. For regimens where risk of FN for the regimen
h the highest recorded risk of FN.
dence intervals* (CIs) for five multivariate models of
Antifungal agents Inpatient visits Outpatient visits
180 (0.075–0.111) 0.138 (0.460–0.129) 2.353 (10.637–7.726)
.014 (0.142–0.087) 3.295 (2.724–4.010) 8.355 (2.151–17.142)
.019 (0.024–0.146) 0.256 (0.011–0.527) 10.959 (4.416–61.247)
.056 (0.297–0.025) 1.471 (1.091–1.954) 28.869 (18.748–36.643)
.049 (0.010–0.133) 1.765 (1.249–2.254) 4.695 (4.759–13.96)
.144 (0.036–0.435) 0.612 (0.037–1.191) 12.616 (22.544–13.965)
.003 (0.013–0.029) 0.093 (0.229–0.024) 0.438 (1.486–2.371)
007 (0.0004–0.00006) 0.001 (0.00004–0.0017) 0.007 (0.021–0.008)
.007 (0.133–0.067) 0.316 (0.061–0.731) 2.440 (3.659–8.371)
.230 (0.116–0.365) 0.184 (0.799–0.449) 1.185 (7.592–10.156)
.009 (0.153–0.061) 1.991 (2.346–1.634) 63.896 (55.670–74.335)
.097 (0.158–0.008) 0.620 (0.021–1.753) 0.920 (17.193–22.657)
.110 (0.196–0.061) 0.180 (0.646–0.334) 2.962 (12.694–6.850)
.011 (0.038–0.066) 0.169 (0.105–0.440) 7.987 (0.148–14.742)
.042 (0.018–0.105) 0.834 (0.443–1.253) 8.891 (0.664–18.990)
.234 (0.002–0.971) 1.188 (0.730–1.827) 7.122 (2.689–17.282)
150 (0.058–0.094) 2.133 (1.644–2.863) 6.051 (1.863–15.848)
.110 (0.014–0.502) 0.146 (0.504–0.279) 2.787 (3.115–10.582)
.006 (0.051–0.064) 0.018 (0.348–0.341) 0.534 (6.491–7.200)
.270 (0.073–0.907) 0.549 (0.243–0.944) 7.988 (0.232–18.487)
.040 (0.160–0.034) 0.868 (0.313–1.49) 29.512 (22.155–38.451)
005 (0.00011–0.000018) 0.00006 (0.0002–0.0004) 0.016 (0.009,0.023)
0.016 0.284 0.270
ootstrap replicates.
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251V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 2 4 7 – 2 5 2effective, largely by reducing costly health care use associated
with FN [25,26].
The data underlying these studies are based on the find-
ings from clinical trials rather than clinical practice. We
sought to evaluate the association between FN, CSF use, and
health care use using claims data from four large payers in
Washington State using observational research methods. In
community settings, we found that patients with FN use sub-
stantially more medical care resources. We also found that
CSFs do not significantly affect health care use when pre-
scribed in a manner consistent with primary prophylaxis.
These findings suggest that CSF, when used appropriately,
may have less of an affect on FN-related health care use than
that observed in clinical trials.
We hypothesize that there are two general explanations
regarding the finding that prophylactic CSF use was not as-
sociated with significant reductions in clinic visits and hos-
pitalizations. The first is factors related to our study design.
First, we compared prophylactic CSF use with other use or
no use. The inclusion of CSF in the comparison group might
have diminished the apparent efficacy of primary prophy-
laxis if a portion of this use was “secondary prophylaxis”;
that is, prophylactic use initiated at the start of subsequent
cycles of chemotherapy following an FN event during the
initial cycle. We are not able to distinguish such use, which
may be effective, from CSF prescribing that was used to
treat established neutropenia without a fever (i.e., afebrile
neutropenia) or FN, where experts agree CSF is ineffective
[13].
The second explanation relates to differences between
how CSF is used in practice versus clinical trials. The patient
population in our sample contains persons who were older
and had greater levels of comorbidity than those participating
in clinical trials. For example, 20% of our breast cancer popula-
ion included Medicare patients, and overall the average age of
he study population was 56 years. In contrast, the average age of
articipants in the largest clinical trial of CSF use in breast cancer
as 52 years [11]. Moreover, 62% of patients in that trial had
etastatic disease compared to 6% in our study. Although sev-
ral studies suggest that the incidence of chemotherapy-in-
uced FN increases with age, [27–29] there is less evidence re-
arding the efficacy of CSF in older patients, particularly with
onhematologic malignancies. If age and noncancer comorbid-
ty influenced the effectiveness of CSF, its influence may be
ess than that observed in trials. We were not able to ob-
erve the doses of chemotherapeutic agents or CSF admin-
stered. CSFs are recommended for dose-dense regimens
sed in breast cancer, because the incidence of FN is greater
han 20%, but such regimens may be given less commonly
n clinical practice than in research settings. If doses of ei-
her chemotherapy or CSF were lower than recommended,
his would diminish the apparent efficacy of CSF on FN
vents and related health use.
This study has several limitations. The timing of CSF and
hemotherapy use was determined by medical claims, which
re subject to coding inaccuracies both in terms of designation
f the drugs and the timing of their administration. As noted,
e did not have information on the dosages and schedule ofhemotherapy that may have influenced CSF use or more de-tailed patient-specific risk factors that guided regimen choice.
We did not have information on physicians, clinics, and hos-
pitals, although all three may have influenced prescribing. Our
findings are restricted to cancer patients Washington State,
reflecting regional practice patterns that may not necessarily
represent the United States as a whole.
We did not have access to reimbursement or pricing data
for all plans that contributed to this study, thus we cannot
determine the incremental cost affects of CSF on total medical
care expenditures for this patient population. Such real-world
data would allow more accurate estimation of the short-term
budget impact and longer term cost-effectiveness of CSF for
patients receiving cytotoxic chemotherapy.
With respect to modeling issues, we believes it was impor-
tant to produce results that were statistically valid and at the
same time easily interpreted. We could have used more so-
phisticated techniques such as two-part models or zero in-
flated Poisson models as the main analytic approach. In a sep-
arate sensitivity analysis, we applied both approaches and the
results showed patterns similar to those reported in terms of
direction and statistical significance. Importantly, with the
modeling approach we used, coefficients are directly interpre-
table as average change and the confidence intervals are cor-
rected for bias; for example, the coefficient for FN is the aver-
age change in outcome comparing patients with FN versus
those without.
In a retrospective evaluation of a diverse sample of patients
with breast, colorectal, or nonsmall cell lung cancer receiving
myelosuppressive chemotherapy as used in clinical practice,
we found that primary prophylactic CSF use was not associ-
ated with a reduction in hospital stays and clinic visits. Febrile
neutropenia was significantly associated with greater health
care use, raising the possibility that more effective use of CSF
in practice may have a beneficial effect on health care use and
cost in community settings.
Supplementary Material
Supplementary material associated with this article can be
found in the online version, at doi:10.1016/j.jval.2010.09.005.
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